Skip Navigation Links
01 December 2020

OCT Company Values: How We Pursue Our Mission and Vision

OCT Company Values: How We Pursue Our Mission and Vision

At Oxford Cannabinoid Technologies (OCT) our mission is to improve lives through the power of cannabinoids. Our vision is to be the best at turning cannabinoids into prescription medication to address the significant unmet medical needs of millions of patients around the world living with severe and chronic pain.

Our company values form the foundation of what we do at OCT, underpinning how we approach the pursuit of our mission and vision as a team. I know from my experience working as a coach, that to set a team up for success you need a strong values-based foundation. When the management team at OCT first came together we spent a good deal of time and energy building that foundation from scratch. Drug development can be a rocky road, pharmaceutical companies like ours face many challenges along the way, so we knew that it was important to have a solid base we could rely on.

As a company, the things we hold most dear are excellence, collaboration, respect, fairness and integrity. Let’s take these in turn, so I can explain why they are so important to us.

Excellence 

For us, this is an end and a means. Developing prescription medications does not happen overnight – it’s a long game. We want to make sure that we remember the journey as well as the destination. So, we make sure to celebrate successes along the way. The pursuit of excellence drives us to care deeply about our company’s mission and the patients that we are ultimately hoping to help. It underpins our commitment to rigorous research and our attention to detail, as we work to develop life-changing treatments for the patients most in need.

Collaboration

We all know the old saying: If you want to go fast, go alone. If you want to go far, go together. We want to go far and, if you ask John Lucas, he’ll tell you we’d like to get there as fast as possible.

The successful outcomes of our research depend upon collaboration. As a tight-knit team, we strive to always be supportive of each other. We are generous with our time, care and expertise. This has created a highly collegiate culture in which we are happy to learn from our mistakes. We recognise that we are better together. This approach extends beyond OCT to our work with external partners who we approach with the same principle of collaboration. It’s this focus on collaboration that has helped us to work seamlessly alongside prestigious academic institutions, such as Oxford University, and to partner with top-tier research organisations.

Respect

Regardless of whether we collaborate as a team or with external partners, we demonstrate high regard for everyone: each other, our stakeholders, and the wider community. By making respect a cornerstone, we empower people to speak up, to take risks and to be vulnerable. Having a respectful workplace culture promotes conversation, encourages people to ask questions, and makes for better outcomes overall.

Fairness

We value authenticity. We don’t want to work with your ‘representative’, we want the real you. We listen to each other and we are prepared to evolve together. Our company is free from discrimination and dishonesty and we treat each other with dignity. We look out for each other’s health and wellbeing. We recognise that people who are valued and nurtured do great work.

Integrity

As a team we are committed to doing the right thing, even when no one is watching. We make sure colleagues and external partners can rely on us: we keep our promises. When something goes wrong, we put our hands up and work together to resolve the issue.

 

This has been a challenging year for everyone and on so many fronts. One of the things that has made a difference here at OCT has been having our values so clearly defined. With such a strong foundation, it’s been easier to ride the 2020 rollercoaster.

As we prepare for the year ahead, we know that those values will continue to support us as we work to fulfil our mission, whatever the future might hold.

 

Author: Clarissa Sowemimo-Coker

Related News articles

  • Oxford Cannabinoid Technologies nearly ready for new Phase 1 trial

    14 November 2022 Proactive Interview
  • StockBox Premiere - Oxford Cannabinoid Technolgies - Programme 1

    06 October 2022 StockBox
  • StockBox Interview - Oxford Cannabinoid Technologies w/ Dr Valentino Parravicini, CSO

    05 October 2022 StockBox
  • StockBox Premiere with Oxford Cannabinoid, Poolbeg Pharma & Destiny Pharma

    05 October 2022 StockBox
  • Cannabinoid Medicine for Pain Treatment with Clarissa Sowemimo-Coker COO Oxford Cannabinoid

    22 August 2022 StockBox
  • Oxford Cannabinoid Technologies has good opportunities in both lead products says analyst

    26 July 2022
  • Outsourcing in Clinical Trials UK & Ireland 2022 Conference – Dr Valentino Parravicini’s Address

    20 June 2022 Conference
  • OCT Investor Update 30 May 2022 - Q&A Questions

    30 May 2022 Investor Questions
  • The Cannabis Conversation: Cannabis Vs. Opioids with Valentino Parravicini

    18 May 2022 Podcast
  • Investor Meet Company Q&A Session

    16 May 2022 Investor Meet
  • Oxford Cannabinoid Technologies Announces Formation of Scientific Advisory Board to Support Clinical Strategy

    25 April 2022 Scientific Advisory Board
  • Updates on Lead Programme 1 (OCT461201) and Programme 2 (OCT130401) - Trigeminal Neuralgia Clinical Trial

    31 March 2022 Programme Update
  • Data from pre-clinical study show positive results

    08 March 2022 Research Update
  • Requisition of General Meeting - Update

    04 March 2022 General Meeting
  • Oxford Cannabinoid Technologies aims to get aggressive share of £42.5bln market by 2027

    24 February 2022
  • Requisition of General Meeting

    18 February 2022 General Meeting
  • Notice of Analyst and Investment Presentation - How to Register

    17 February 2022 Presentations
  • Oxford Cannabinoid Technologies in drug development deal with Oxford StemTech

    18 November 2021 StemTech
  • Oxford Cannabinoid Technologies in drug development deal with Oxford StemTech

    17 November 2021 R&D Support
  • Posting of Annual Report, Notice of AGM and Form of Proxy

    27 October 2021 Annual Report, Notice of AGM and Form of Proxy
  • OCT Results and Company Update

    18 October 2021 Results and Company Update
  • Final Results and Notice of Annual General Meeting 13th October 2021

    13 October 2021 RNS
  • Oxford Cannabinoid Technologies work on treatment for chronic, painful disease Trigeminal Neuralgia

    12 October 2021 Trigeminal Neuralgia Interview
  • Oxford Cannabinoid Technologies Targets Chronic Pain Condition with Latest Formulation

    11 October 2021 Program 2 Announcement
  • OCT Explore the Opioid Crisis and Chronic Pain Pandemic in Pharmafocus Magazine

    30 September 2021 Pharmafocus Article
  • Good shape, good budget and on track for Oxford Cannabinoid Technologies Holdings

    28 September 2021 Podcast
  • Oxford Cannabinoid Technologies' deal for exclusive access to Canopy Growth's cannabinoid library

    22 September 2021 Canopy Growth
  • Oxford Cannabinoid Technologies says admission to the OTCQB is a logical next step

    02 September 2021 US Market
  • Oxford Cannabinoid Technologies announces strategic partnership with Evotec

    06 July 2021 Partnership
  • Chief Scientific Officer Valentino Parravicini to speak at major cannabinoid-based drugs summit in Boston, Massachusetts

    Chief Scientific Officer Valentino Parravicini to speak at major cannabinoid-based drugs summit in Boston, Massachusetts

    24 June 2021 iCDP Speaker
  • Meet the Team Interview Series: Dr John Lucas, Chief Executive Officer

    Meet the Team Interview Series: Dr John Lucas, Chief Executive Officer

    22 June 2021 Meet the Team Interview Series
  • Oxford Cannabinoid Technologies Holdings plc to conduct live presentations to retail investors

    04 June 2021 Live Presentation
  • OCT Forges Partnership with Voisin Consulting Life Sciences

    OCT Forges Partnership with Voisin Consulting Life Sciences

    01 June 2021 OCT Partnership
  • Oxford Cannabinoid Technologies Announces Changes to Executive Team

    11 January 2021 Oxford Cannabinoid Technologies Announces Changes to Executive Team
  • OCT Company Values: How We Pursue Our Mission and Vision

    OCT Company Values: How We Pursue Our Mission and Vision

    01 December 2020 OCT Company Values
  • OCT - Meet the Team Interview Series: Valentino Parravicini, Chief Scientific Officer

    Meet the Team Interview Series: Dr Valentino Parravicini, Chief Scientific Officer

    26 October 2020 Meet the Team Interview Series
  • OCT - A Pharmaceutical Company Focused on Developing Cannabinoids to Pain

    07 September 2020 OCT - A Pharmaceutical Company Focused on Developing Cannabinoids to Pain
  • OCT Appoints Dr Valentino Parravicini as Chief Scientific Officer as the business prepares for exciting new developments

    OCT Appoints Dr Valentino Parravicini as Chief Scientific Officer

    28 July 2020 OCT Press Release
  • Cannabinoids in medicine part 5: Treating COVID-19

    17 June 2020 Open Access Government
  • Why the Government should continue to invest in Life Sciences post COVID-19

    Why the government should continue to invest in Life Sciences post COVID-19

    01 June 2020 OCT blog - John Lucas, COO
  • OCT researchers publish new study examining genes involved in treating neuropathic pain

    19 April 2020 OCT Press Release
  • OCT announces pre-clinical development of new cannabinoid compound ‘OCT461201’ to treat IBS

    03 April 2020 OCT Press Release
  • Cannabinoids in medicine part 4: Epilepsy

    30 March 2020 Open Access Government
  • Cannabinoids in Medicine Part 3: Psoriasis and Rheumatoid Arthritis

    07 January 2020 Open Access Government
  • Cannabinoids in medicine Part 2: Pain

    11 October 2019 Open Access Government
  • Cannabinoids in medicine Part 1: Cancer

    22 August 2019 Open Access Government
  • An interview with Neil Mahapatra

    08 January 2019 The Times Magazine
  • High life: the start-up hoping to unlock the secrets of medical cannabis

    09 August 2018 Evening Standard
  • Oxford Cannabinoid Technologoies goes global as it announces close of series a fundraising round and management team line-up

    28 June 2018 OCT Press Release
  • Embracing the medical potential of cannabinoids

    01 June 2017 The Medicine Maker
  • Smashing the stigma with science

    01 June 2017 The Medicine Maker
  • Oxford University launches £10m research project into medical marijuana

    16 March 2017 Evening Standard
  • Oxford University launches £10m marijuana research programme

    16 March 2017 BBC
  • Oxford University to launch multimillion-dollar medical marijuana research program

    16 March 2017 CNBC
  • Oxford University to launch study on medical benefits of marijuana

    16 March 2017 The Telegraph
  • The University of Oxford and Kingsley Capital Partners announce ground breaking Cannabinoid Biomedicine Research Programme

    15 March 2017 OCT Press Release